NCT03694262 - The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

March 30, 2023

Study Completion Date

January 5, 2026

Conditions

Endometrial CancerUterine Carcinosarcoma

Interventions

DRUG

Rucaparib

Rucaparib 600mg orally twice daily by continuous dosing

DRUG

Bevacizumab

15mg/kg IV on day 1 of every cycle

DRUG

Atezolizumab

1,200mg IV on day 1 of every cycle

Trial Locations (3)

Mount Sinai, New York

St. Luke's Hospital and Health Network, Bethlehem

Froedtert Lutheran Memorial Hospital, Milwaukee